Underrepresentation of female subjects in BE study to register Generic [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-03-15 08:30 (1920 d 00:18 ago) – Posting: # 21272
Views: 6,150

Hi,

❝ Can we conduct the pivotal study only in Males? Can we extrapolate the conclusions obtained in males to females. What would be the regulatory challenges and please prove some references that can guide me on this.


FDA? Even if not FDA I don't think your justification will work. You are trying not to use female subjects because they caused your study to fail. That alone is not a good justification.

J

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
23 visitors (0 registered, 23 guests [including 18 identified bots]).
Forum time: 09:48 CEST (Europe/Vienna)

In matters of style, swim with the current;
in matters of principle, stand like a rock.    Thomas Jefferson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5